Aclaris Therapeutics, Inc. is a clinical stage specialty pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated therapies to address significant unmet needs in dermatology
Quote | Aclaris Therapeutics Inc. (NASDAQ:ACRS)
Last: | $1.34 |
---|---|
Change Percent: | 0.76% |
Open: | $1.3 |
Close: | $1.34 |
High: | $1.36 |
Low: | $1.28 |
Volume: | 726,991 |
Last Trade Date Time: | 05/07/2024 03:00:00 am |
News | Aclaris Therapeutics Inc. (NASDAQ:ACRS)
2024-05-07 16:04:20 ET More on Aclaris Therapeutics Aclaris Therapeutics GAAP EPS of -$0.02 beats by $0.31, revenue of $17.6M beats by $12.55M Seeking Alpha’s Quant Rating on Aclaris Therapeutics Historical earnings data for Aclaris Therapeutics Financ...
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidat...
Message Board Posts | Aclaris Therapeutics Inc. (NASDAQ:ACRS)
Subject | By | Source | When |
---|---|---|---|
I was short premarket 20.30 then quickly covered | alchemytrader | investorshub | 01/20/2021 10:19:02 PM |
ACRS offering more than 5m shares at $17.50/per share | SteevoTrader | investorshub | 01/20/2021 2:01:58 PM |
The way she kept grinding back to 19s | alchemytrader | investorshub | 01/20/2021 4:50:21 AM |
Are we seeing a dump tomorrow? | SteevoTrader | investorshub | 01/20/2021 1:57:36 AM |
Oh really? hit 19.95 today... | alchemytrader | investorshub | 01/20/2021 12:55:29 AM |
News, Short Squeeze, Breakout and More Instantly...
Aclaris Therapeutics Inc. Company Name:
ACRS Stock Symbol:
NASDAQ Market:
Aclaris Therapeutics Inc. Website:
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidat...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...
BioCryst Pharmaceuticals (NASDAQ: BCRX) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.23. T...